H. Ç. Yıldırım Et Al. , "The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.," International journal of clinical oncology , 2024
Yıldırım, H. Ç. Et Al. 2024. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.. International journal of clinical oncology .
Yıldırım, H. Ç., Kutlu, Y., Mutlu, E., Aykan, M. B., Korkmaz, M., Yalçın, S., ... Şakalar, T.(2024). The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.. International journal of clinical oncology .
Yıldırım, Hasan Et Al. "The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.," International journal of clinical oncology , 2024
Yıldırım, Hasan Ç. Et Al. "The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.." International journal of clinical oncology , 2024
Yıldırım, H. Ç. Et Al. (2024) . "The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.." International journal of clinical oncology .
@article{article, author={Hasan Çağrı Yıldırım Et Al. }, title={The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.}, journal={International journal of clinical oncology}, year=2024}